Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cognitive impairment in Chinese adult patients with type III spinal muscular atrophy without disease-modifying treatment. | Front Neurol | 2023 | 38020636 | PubTator, text mining | PubMed |
| Study of lncRNAs in Pediatric Neurological Diseases: Methods, Analysis of the State-of-Art and Possible Therapeutic Implications. | Pharmaceuticals (Basel) | 2023 | 38004481 | PubTator, text mining | PubMed |
| Concepts of Regeneration for Spinal Diseases in 2023. | Int J Mol Sci | 2023 | 38003526 | PubTator, text mining | PubMed |
| Development of 2'-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells. | Biomedicines | 2023 | 38002071 | PubTator, text mining | PubMed |
| Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea. | Yonsei Med J | 2023 | 37992742 | PubTator, text mining | PubMed |
| Nucleolar reorganization after cellular stress is orchestrated by SMN shuttling between nuclear compartments. | Nat Commun | 2023 | 37968267 | PubTator, text mining | PubMed |
| Studying carrier frequency of spinal muscular atrophy in the State of Qatar and comparison to other ethnic groups: Pilot study. | Mol Genet Genomic Med | 2023 | 37964750 | PubTator, text mining | PubMed |
| Gene therapy-based strategies for spinal muscular atrophy-an Asia-Pacific perspective. | Mol Cell Pediatr | 2023 | 37964159 | PubTator, text mining | PubMed |
| SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy. | Commun Biol | 2023 | 37957344 | PubTator, text mining | PubMed |
| Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations. | Sci Rep | 2023 | 37957262 | PubTator, text mining | PubMed |
| Astrogliosis in multiple sclerosis and neuro-inflammation: what role for the notch pathway? | Front Immunol | 2023 | 37936690 | PubTator, text mining | PubMed |
| An Effective and Universal Long-Read Sequencing-Based Approach for SMN1 2 + 0 Carrier Screening through Family Trio Analysis. | Clin Chem | 2023 | 37932106 | PubTator, text mining | PubMed |
| Identifying Clinical and Genetic Characteristics of Spinal Muscular Atrophy Patients and Families in Saudi Arabia. | Cureus | 2023 | 37927698 | PubTator, text mining | PubMed |
| Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports. | BMC Neurol | 2023 | 37907848 | PubTator, text mining | PubMed |
| Current State of Human Gene Therapy: Approved Products and Vectors. | Pharmaceuticals (Basel) | 2023 | 37895887 | PubTator, text mining | PubMed |
| Unlocking the Complexity of Neuromuscular Diseases: Insights from Human Pluripotent Stem Cell-Derived Neuromuscular Junctions. | Int J Mol Sci | 2023 | 37894969 | PubTator, text mining | PubMed |
| RNA-Based Therapeutic Technology. | Int J Mol Sci | 2023 | 37894911 | PubTator, text mining | PubMed |
| An Induced Pluripotent Stem Cell-Derived Human Blood-Brain Barrier (BBB) Model to Test the Crossing by Adeno-Associated Virus (AAV) Vectors and Antisense Oligonucleotides. | Biomedicines | 2023 | 37893074 | PubTator, text mining | PubMed |
| Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy. | J Clin Med | 2023 | 37892834 | PubTator, text mining | PubMed |
| Research Progress on the Structural and Functional Roles of hnRNPs in Muscle Development. | Biomolecules | 2023 | 37892116 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=21